NMTC Stock Overview
A medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
NeuroOne Medical Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.62 |
| 52 Week High | US$1.39 |
| 52 Week Low | US$0.40 |
| Beta | 0.65 |
| 1 Month Change | 30.89% |
| 3 Month Change | -43.56% |
| 1 Year Change | -46.50% |
| 3 Year Change | 5.70% |
| 5 Year Change | -87.42% |
| Change since IPO | -94.87% |
Recent News & Updates
Recent updates
NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead
Dec 10Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?
Dec 16
Can NeuroOne Medical Technologies (NASDAQ:NMTC) Afford To Invest In Growth?
Jul 25Here's Why We're Watching NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Situation
Apr 11We Think NeuroOne Medical Technologies (NASDAQ:NMTC) Needs To Drive Business Growth Carefully
Sep 15NeuroOne rallies on receiving $3.5M in accelerated milestone payment from Zimmer Biomet
Aug 03Is NeuroOne Medical Technologies (NASDAQ:NMTC) In A Good Position To Deliver On Growth Plans?
Jun 02Companies Like NeuroOne Medical Technologies (NASDAQ:NMTC) Could Be Quite Risky
Dec 18NeuroOne: Thin Film Electrodes For Diagnosis And Treatment Of Neurological Conditions
Nov 19Will NeuroOne Medical Technologies (NASDAQ:NMTC) Spend Its Cash Wisely?
Sep 04We're Not Very Worried About NeuroOne Medical Technologies' (NASDAQ:NMTC) Cash Burn Rate
May 27Shareholder Returns
| NMTC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.5% | 0.3% | 0.3% |
| 1Y | -46.5% | 8.2% | 8.0% |
Return vs Industry: NMTC underperformed the US Medical Equipment industry which returned 8.2% over the past year.
Return vs Market: NMTC underperformed the US Market which returned 8% over the past year.
Price Volatility
| NMTC volatility | |
|---|---|
| NMTC Average Weekly Movement | 16.6% |
| Medical Equipment Industry Average Movement | 9.7% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: NMTC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NMTC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 17 | Dave Rosa | nmtc1.com |
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, radio frequency and brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company also focuses on applications of its technology associated with artificial intelligence.
NeuroOne Medical Technologies Corporation Fundamentals Summary
| NMTC fundamental statistics | |
|---|---|
| Market cap | US$29.15m |
| Earnings (TTM) | -US$7.19m |
| Revenue (TTM) | US$5.75m |
5.1x
P/S Ratio-4.1x
P/E RatioIs NMTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMTC income statement (TTM) | |
|---|---|
| Revenue | US$5.75m |
| Cost of Revenue | US$7.76m |
| Gross Profit | -US$2.01m |
| Other Expenses | US$5.17m |
| Earnings | -US$7.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | -0.15 |
| Gross Margin | -35.03% |
| Net Profit Margin | -125.02% |
| Debt/Equity Ratio | 0% |
How did NMTC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 18:26 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeuroOne Medical Technologies Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Nowak | Craig-Hallum Capital Group LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |